NCT01263379View on ClinicalTrials.gov

Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 5, 2010

Primary Completion Date

March 9, 2022

Study Completion Date

March 9, 2022

Conditions
Epidermolysis Bullosa DystrophicaEpidermolysis Bullosa
Interventions
BIOLOGICAL

LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

"This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein."

Trial Locations (1)

94063

Stanford University, School of Medicine, Dept of Dermatology, Redwood City

Sponsors
All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

collaborator

Stanford University

OTHER

lead

Abeona Therapeutics, Inc

INDUSTRY